This study is for people with HIV who have been on a specific HIV medicine called B/F/TAF and have their virus under control. The study wants to see if a new medicine, taken once a week, works as well as the current daily medicine. The new medicine is called Islatravir/Lenacapavir (ISL/LEN). HIV, or Human Immunodeficiency Virus, is a virus that attacks the body's immune system. This study will last for 48 weeks, and participants must have had low virus levels for at least 6 months before joining. They cannot have had certain infections or issues with their liver. Some other requirements are related to past medical history and current health status.

• Participants will be in the study for 48 weeks.
• The study compares a weekly pill to the current daily treatment.
• Participants must have controlled virus levels for at least 6 months.